Health Care·Pharmaceuticals·$3.0B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.26 | N/A | +31.94% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.26 | N/A | +31.94% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Management expressed a cautious optimism about future projects. They are committed to navigating current challenges while advancing their pipeline.
Management highlighted ongoing efforts to advance their pipeline.
They acknowledged the challenges in the current market environment.
Focus remains on strategic partnerships and product development.
Nektar Therapeutics reported a wider-than-expected loss per share but did not provide revenue figures. The stock fell 4.18% following the earnings report, likely due to the lack of revenue data and guidance. Investors may be concerned about the company's ability to navigate current market challenges without clear direction.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
ROPER TECHNOLOGIES I
Jul 28, 2014